The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Drug startups have banked $6 billion in IPOs so far in 2026, more than the combined amount raised by this point in the previous four years.

    Updated 12 hours ago
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

    Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

  • Portrait of a brown-haired man smiling at the camera.
    Image attribution tooltip
    Permission granted by HI-Bio
    Image attribution tooltip
    IPO window

    Cardiac drug developer Braveheart banks more than $382M in IPO

    Braveheart is one of five biotechnology firms that made plans to price an IPO this week. They could collectively raise more than $1 billion from public investors.

    Updated Aug. 6, 2026
  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive
    Image attribution tooltip
    Tracker

    10 clinical trials to watch in the second half of 2026

    The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.

  • A Moderna logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip
    Vaccines

    FDA approves Moderna’s mRNA flu vaccine

    The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory turnaround.

    FDA
  • A picture of CDC director Erica Schwartz testifying at a Senate confirmation hearing.
    Image attribution tooltip
    Finn Gomez / Staff via Getty Images
    Image attribution tooltip
    Vaccines

    Erica Schwartz confirmed as next CDC director

    Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief. 

    FDA
  • An AstraZeneca logo stands atop an office building in Shanghai, China.
    Image attribution tooltip
    Robert Way via Getty Images
    Image attribution tooltip

    An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

    In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.

  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly climbs, Novo falls as obesity drug battle intensifies

    A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

  • Front view of the NASDAQ MarketSite, which occupies the northwest corner at the base of the 4 Times Square building, in Midtown Manhattan, New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Attovia adds to biotech IPO momentum with $289M offering

    The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.

  • A 3D illustration of a pair of lungs inside the rib cage.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    A COPD drug from China draws $115M in venture funding

    Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.

  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex’s biggest overhang: a rival 50 times smaller

    Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.

  • Pfizer HQ entrance
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip

    Pfizer expands multibillion-dollar cost-cutting plan

    Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.

  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire.

    BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.

    Updated Aug. 4, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    J&J pharma leader to retire; Krystal slumps on gene therapy miss

    Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

  • An Alnylam logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Alnylam plunges as earnings deliver ‘one-two punch’

    The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

  • Sign reads "wall street" with "stock exchange" engraved on a building in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Supernus, Indivior merge to beef up brain drug portfolio

    The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.

  • A BioNTech logo hangs on the side of an office building.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    BioNTech taps Sobi executive Oelkers as its next CEO

    Guido Oelkers will guide BioNTech’s ongoing transition into an oncology-focused biotech, while co-founder and longtime leader Ugur Sahin prepares to join a fledgling mRNA startup.

  • An anatomical model of the heart sits on a desk in a doctor's office
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novo setback casts doubt on a new way to treat heart disease

    Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different cardiovascular drugs that also target inflammation.

  • Bunches of pills in varied colors are organized in containers.
    Image attribution tooltip
    Fotografia Basica via Getty Images
    Image attribution tooltip

    Trump administration tries again to institute rebates in 340B

    The Health Resources and Services Administration is again pushing to include rebates in the drug discount program after a failed attempt earlier this year. Hospitals railed against the announcement, saying it would burden already strapped providers.

  • Resilience's headquarters in Blue Ash, Cincinnati.
    Image attribution tooltip
    Courtesy of Resilience
    Image attribution tooltip

    Resilience and Lilly invest $750M to boost Cincinnati drug production

    The expansion will create 400 jobs dedicated to making GLP-1 injectables across Resilience’s contract manufacturing facilities.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Replimune melanoma drug wins support of FDA panel

    The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

    Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

  • Johnson & Johnson's pharmaceutical office in Madrid, Spain.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B

    The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.

  • Wall Street buildings
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push

    Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.

  • An illustration of two neurons, colored blue and purple
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    MapLight CEO on what investors missed in the biotech’s schizophrenia data

    Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."